Increasing FcaγRIIa affinity of an FcaγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity

mAbs

Volumn 6, Issue 2, 2014, Pages 409-421

  Derer, Stefanie ^a   Glorius, Pia ^a   Schlaeth, Martin ^a   Lohse, Stefan ^a   Klausz, Katja ^a   Muchhal, Umesh ^a   Desjarlais, John R ^b   Humpe, Andreas ^a   Valerius, Thomas ^a   Peipp, Matthias ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b Xencor Inc   (United States)

Author keywords

ADCC; Cetuximab; EGFR; Fc engineering; Fc RIIa; Fc RIII; Fc RIIIb; PMN

Indexed keywords

ANTIGEN; CD16 ANTIGEN; CD32 ANTIGEN; CD89 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC RECEPTOR IIA; UNCLASSIFIED DRUG; CETUXIMAB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECEPTOR BINDING; EOSINOPHIL; HUMAN; HUMAN CELL; NEUTROPHIL; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROTEIN ENGINEERING; SURFACE PLASMON RESONANCE; ANTIBODY AFFINITY; CELL CULTURE; EGFR; FC-ENGINEERING; FCΓRIIA; FCΓRIII; FCΓRIIIB; GENETIC POLYMORPHISM; GENETICS; GLYCOSYLATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PMN;

ADCC; CETUXIMAB; EGFR; FC-ENGINEERING; FCΓRIIA; FCΓRIII; FCΓRIIIB; PMN;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; EOSINOPHILS; GLYCOSYLATION; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; NEUTROPHILS; POLYMORPHISM, GENETIC; PROTEIN ENGINEERING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG;

EID: 84896535626     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27457     Document Type: Article

References (57)

1. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009; 373:1033-40; PMID:19304016; http://dx.doi. org/10.1016/S0140-6736(09)60251-8
2. WHO. The world health report - Health systems financing: the path to universal coverage. 2010.
3. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
4. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704
5. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010; 70:3209-17; PMID:20354182; http://dx.doi.org/10.1158/0008-5472.CAN-09-4109
6. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659-69; PMID:15210744; http://dx.doi.org/10.1084/jem.20040119
7. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005; 310:1510-2; PMID:16322460; http://dx.doi.org/10.1126/science.1118948
8. Valerius T. Fcgamma receptor polymorphisms as biomarkers for epidermal growth factor receptor antibodies. J Clin Oncol 2010; 28:e393, author reply e394-6; PMID:20547983; http://dx.doi.org/10.1200/JCO.2010.28.7342
9. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754
10. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96; PMID:18347005; http://dx.doi.org/10.1200/JCO.2007.14.8957
11. Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004; 103:1472-4; PMID:14563637; http://dx.doi.org/10.1182/blood-2003-07-2548
12. Peipp M, Dechant M, Valerius T. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 2008; 20:436-43; PMID:18585454; http://dx.doi.org/10.1016/j.coi.2008.05.012
13. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25:3712-8; PMID:17704420; http://dx.doi.org/10.1200/JCO.2006. 08.8021
14. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27:1122-9; PMID:19164213; http://dx.doi.org/10.1200/JCO.2008.18.0463
15. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-57; PMID:16622479; http://dx.doi.org/10.1038/nri1837
16. Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166:2571-5; PMID:11160318
17. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005-10; PMID:16537476; http://dx.doi. org/10.1073/pnas.0508123103
18. Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011; 108:12669-74; PMID:21768335; http://dx.doi.org/10.1073/pnas.1108455108
19. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200
20. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200
21. Jefferis R, Lund J, Goodall M. Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation. Immunol Lett 1995; 44:111-7; PMID:7797239; http://dx.doi.org/10.1016/0165-2478(94)00201-2
22. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG, et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008; 112:2390-9; PMID:18566325; http://dx.doi.org/10.1182/blood- 2008-03-144600
23. van Egmond M, Bakema JE. Neutrophils as effector cells for antibody-based immunotherapy of cancer. Semin Cancer Biol 2013; 23:190-9; PMID:23287459; http://dx.doi.org/10.1016/j.semcancer.2012.12.002
24. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 2007; 12:898-910; PMID:17993407; http://dx.doi.org/10.1016/j. drudis.2007.08.009
25. Heijnen IA, Rijks LJ, Schiel A, Stockmeyer B, van Ojik HH, Dechant M, Valerius T, Keler T, Tutt AL, Glennie MJ, et al. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies. J Immunol 1997; 159:5629-39; PMID:9548506
26. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184:512-20; PMID:19949082; http://dx.doi.org/10.4049/jimmunol.0900847
27. Biburger M, Aschermann S, Schwab I, Lux A, Albert H, Danzer H, Woigk M, Dudziak D, Nimmerjahn F. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 2011; 35:932-44; PMID:22169040; http://dx.doi.org/10.1016/j.immuni.2011.11.009
28. Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol 2009; 183:4782-91; PMID:19748990; http://dx.doi.org/10.4049/jimmunol.0900699
29. Siders WM, Shields J, Garron C, Hu Y, Boutin P, Shankara S, Weber W, Roberts B, Kaplan JM. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma 2010; 51:1293-304; PMID:20377308; http://dx.doi.org/10.3109/10428191003777963
30. Albanesi M, Mancardi DA, Jönsson F, Iannascoli B, Fiette L, Di Santo JP, Lowell CA, Bruhns P. Neutrophils mediate antibody-induced antitumor effects in mice. Blood 2013; 122:3160-4; PMID:23980063; http://dx.doi.org/10.1182/ blood-2013-04-497446
31. Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173:889-97; PMID:1706752; http://dx.doi.org/10.1084/jem.173.4.889
32. Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, Golay J. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 2013; 190:231-9; PMID:23225880; http://dx.doi.org/10.4049/jimmunol. 1202645
33. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi.org/10. 1038/nri2206
34. Unkeless JC, Scigliano E, Freedman VH. Structure and function of human and murine receptors for IgG. Annu Rev Immunol 1988; 6:251-81; PMID:2968084; http://dx.doi.org/10.1146/annurev.iy.06.040188.001343
35. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119:5640-9; PMID:22535666; http://dx.doi.org/10.1182/blood-2012-01-380121
36. Shibata-Koyama M, Iida S, Misaka H, Mori K, Yano K, Shitara K, Satoh M. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 2009; 37:309-21; PMID:19218011; http://dx.doi.org/10. 1016/j.exphem.2008.11.006
37. Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013; 122:3482-91; PMID:24106207; http://dx.doi.org/10.1182/blood-2013-05-504043
38. Breunis WB, van Mirre E, Geissler J, Laddach N, Wolbink G, van der Schoot E, de Haas M, de Boer M, Roos D, Kuijpers TW. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum Mutat 2009; 30:E640-50; PMID:19309690; http://dx.doi.org/10.1002/humu.20997
39. Willcocks LC, Lyons PA, Clatworthy MR, Robinson JI, Yang W, Newland SA, Plagnol V, McGovern NN, Condliffe AM, Chilvers ER, et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med 2008; 205:1573-82; PMID:18559452; http://dx.doi.org/10.1084/jem.20072413
40. Huizinga TW, Dolman KM, van der Linden NJ, Kleijer M, Nuijens JH, von dem Borne AE, Roos D. Phosphatidylinositol-linked FcRIII mediates exocytosis of neutrophil granule proteins, but does not mediate initiation of the respiratory burst. J Immunol 1990; 144:1432-7; PMID:2137491
41. Salmon JE, Brogle NL, Edberg JC, Kimberly RP. Fc gamma receptor III induces actin polymerization in human neutrophils and primes phagocytosis mediated by Fc gamma receptor II. J Immunol 1991; 146:997-1004; PMID:1824853
42. Chen K, Nishi H, Travers R, Tsuboi N, Martinod K, Wagner DD, Stan R, Croce K, Mayadas TN. Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIA in vivo. Blood 2012; 120:4421-31; PMID:22955924; http://dx.doi.org/10.1182/blood-2011-12-401133
43. Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J Immunol 2013; 190:4315-23; PMID:23509345; http://dx.doi.org/10.4049/jimmunol.1200501
44. Kurlander RJ. Blockade of Fc receptor-mediated binding to U-937 cells by murine monoclonal antibodies directed against a variety of surface antigens. J Immunol 1983; 131:140-7; PMID:6223069
45. Fanger MW, Shen L, Graziano RF, Guyre PM. Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 1989; 10:92-9; PMID:2525910; http://dx.doi.org/10.1016/0167-5699(89)90234-X
46. Tsuboi N, Asano K, Lauterbach M, Mayadas TN. Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity 2008; 28:833-46; PMID:18538590; http://dx.doi.org/10.1016/j.immuni.2008.04.013
47. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7:2517-27; PMID:18723496; http://dx.doi.org/10.1158/1535-7163.MCT-08-0201
48. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186:3762-9; PMID:21296976; http://dx.doi.org/10.4049/jimmunol.1000303
49. Peipp M, van de Winkel JG, Valerius T. Molecular engineering to improve antibodies' anti-lymphoma activity. Best Pract Res Clin Haematol 2011; 24:217-29; PMID:21658620; http://dx.doi.org/10.1016/j.beha.2011.03.004
50. Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today 2012; 17:954-63; PMID:22561895; http://dx.doi.org/10.1016/j.drudis. 2012.04.006
51. Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012; 4:419-25; PMID:22699226; http://dx.doi.org/10. 4161/mabs.20996
52. Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2011; 29:3783-90; PMID:21900113; http://dx.doi.org/10.1200/JCO.2011.34.8888
53. Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012; 4:419-25; PMID:22699226; http://dx.doi.org/10. 4161/mabs.20996
54. Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012; 119:5126-32; PMID:22431570; http://dx.doi.org/10.1182/blood-2012-01-404368
55. van Oers MHJ. CD20 antibodies: type II to tango? Blood 2012; 119:5061-3; PMID:22653951; http://dx.doi.org/10.1182/blood-2012-04-420711
56. Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW. A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol 2007; 44:1986-98; PMID:17079018; http://dx.doi.org/10.1016/j.molimm. 2006.09.029
57. Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, et al. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J Immunol Methods 2011; 373:67-78; PMID:21855548; http://dx.doi.org/10.1016/j.jim.2011.08.003